☆ 4.4 Article

One-Month Dual Antiplatelet Therapy in Patients With Chronic and Acute Coronary Syndromes Treated With Bioresorbable Polymer Everolimus-Eluting Stents

AMERICAN JOURNAL OF CARDIOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Cardiac & Cardiovascular Systems

Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench to bedside

Johny Nicolas et al.

Summary: Coronary stents have revolutionized the treatment of coronary artery disease. The introduction of new-generation drug-eluting stents has greatly improved the safety and efficacy compared to bare-metal stents. There are now over 20 different DES types available, each with its unique features and characteristics. The clinical implications of stent design in high-risk subsets of patients are also discussed.

CARDIOVASCULAR RESEARCH (2023)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Recognized Outstanding Reviewers for Circulation in 2021

Darren K. McGuire et al.

CIRCULATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction

Johny Nicolas et al.

Summary: Patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) are at increased risk for bleeding complications compared to patients with chronic coronary syndrome (CCS), with AMI patients more likely to experience thrombotic and bleeding complications. The ARC-HBR criteria successfully identified patients with AMI and CCS who had an increased risk for bleeding complications at 1-year follow-up post-PCI.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial

Laura S. M. Kerkmeijer et al.

Summary: This study provides the final five-year clinical follow-up of the Absorb BVS compared with the XIENCE EES. The results show that the excess risk of the Absorb BVS on late adverse events, particularly device thrombosis, continues up to 4 years and seems to plateau afterwards. Prolonged dual antiplatelet therapy has a certain effect on events in the scaffold group.

EUROINTERVENTION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States

Dylan L. Steen et al.

Summary: Patients with acute coronary syndrome (ACS) remain at a very high risk of experiencing recurrent cardiovascular events, particularly early after discharge. Among different subgroups, patients without revascularization and with a Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention >= 4 had the highest 5-year event rate for the primary cardiovascular end point.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis

Anne H. Tavenier et al.

Summary: Based on analysis of five randomized controlled trials, DAPT de-escalation was associated with significant reduction in bleeding events and major adverse cardiac events compared to standard DAPT. Both unguided and guided DAPT de-escalation strategies, whether guided by genetic testing or platelet function testing (PFT), showed consistent lowering rates of bleeding and ischemic events.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome The STOPDAPT-2 ACS Randomized Clinical Trial

Hirotoshi Watanabe et al.

Summary: In patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy (DAPT) did not demonstrate noninferiority to 12 months of DAPT for the composite end point of cardiovascular and bleeding events.

JAMA CARDIOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial

Yong-Joon Lee et al.

Summary: This study compared the impact of 1-month dual antiplatelet therapy (DAPT) followed by aspirin monotherapy and 6-12-month DAPT followed by aspirin monotherapy according to clinical presentation. The results showed that for patients with stable coronary artery disease (CAD), 1-month DAPT followed by aspirin monotherapy had lower rates of major adverse cardiac and cerebrovascular events compared to 6-12-month DAPT followed by aspirin monotherapy. However, for patients with acute coronary syndrome (ACS), there were no significant differences in the primary outcome between the two therapy groups.

EUROINTERVENTION (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk

Pieter C. Smits et al.

Summary: This study investigated the safety and efficacy of an abbreviated antiplatelet therapy (APT) regimen after coronary stenting in high bleeding risk patients with acute or recent myocardial infarction. The results showed that, compared to a nonabbreviated APT strategy, stopping dual APT after one month and switching to single APT reduced bleeding events without increasing adverse clinical outcomes and major adverse cardiac and cerebral events in high bleeding risk patients.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Jean-Philippe Collet et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome The HOST-REDUCE-POLYTECH-ACS Trial

Hyo-Soo Kim et al.

Summary: The study demonstrated that in patients with acute coronary syndrome (ACS), durable polymer drug-eluting stents (DP-DES) were noninferior to biodegradable polymer DES (BP-DES) in terms of patient-oriented composite outcomes at 12 months after percutaneous coronary intervention.

CIRCULATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Primary Results of the EVOLVE Short DAPT Study Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent

Ajay J. Kirtane et al.

Summary: The EVOLVE Short DAPT study showed that in high bleeding risk patients treated with the SYNERGY everolimus-eluting stent, discontinuing P2Y(12) inhibitor after 3 months while continuing aspirin led to favorable ischemic outcomes.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Outcomes of Drug-Eluting Stent Thrombosis After Treatment for Acute Versus Chronic Coronary Syndrome

Fumi Yamamoto et al.

Summary: This study assessed the association between clinical presentation at index procedure and mortality in patients with second-generation drug-eluting stent thrombosis. The results showed that the cumulative 3-year incidence of all-cause death after the index ST events was similar between patients with acute coronary syndrome (ACS) and chronic coronary syndrome (CCS), but patients in the ACS group were more likely to have early ST and higher incidences of target lesion revascularization and recurrent ST compared to the CCS group.

JACC-CARDIOVASCULAR INTERVENTIONS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation One-Month DAPT Trial

Sung-Jin Hong et al.

Summary: The study found that among patients with noncomplex coronary artery disease, 1-month DAPT followed by aspirin monotherapy after PF-DCS implantation was noninferior to 6-to 12-month DAPT after BP-DES implantation for the 1-year composite of cardiovascular events or major bleeding.

JACC-CARDIOVASCULAR INTERVENTIONS (2021)

Add to Collection

Article Medicine, General & Internal

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Marco Valgimigli et al.

Summary: The study showed that one month of dual antiplatelet therapy was noninferior to continuing therapy for at least 2 additional months in terms of net adverse clinical events and major adverse cardiac or cerebral events in patients with high risk of bleeding after drug-eluting stent implantation; abbreviated therapy also resulted in a lower incidence of major or clinically relevant nonmajor bleeding.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis

Raffaele Piccolo et al.

Summary: Studies have shown that major and late bleeding in patients with coronary artery disease is associated with a similar increase in mortality compared to myocardial infarction, while early bleeding may have a stronger association with mortality.

EUROINTERVENTION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial

Pascal Vranckx et al.

Summary: This study analyzed the outcomes of dual antiplatelet therapy after coronary drug-eluting stent placement in patients with stable coronary artery disease (SCAD) and acute coronary syndromes (ACS). It was found that the experimental strategy could reduce bleeding risk in ACS patients, but the effect was not significant in SCAD patients.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Current management and prognosis of patients with recurrent myocardial infarction

Leonardo De Luca et al.

Summary: Recurrent myocardial infarction is a common occurrence following acute coronary syndrome, particularly in the first year, with patients at higher risk of cardiovascular events and mortality. Prevention strategies include complete coronary revascularization, effective dual antiplatelet therapy, and secondary prevention measures, although there is ongoing controversy and lack of dedicated studies on the management of re-MI.

REVIEWS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Bioresorbable polymer and durable polymer metallic stents in coronary artery disease: a meta-analysis

Tanveer Mir et al.

Summary: Studies comparing bioresorbable-polymer-stents (BPS) and second-generation durable-polymer-stents (DPS) in percutaneous coronary intervention (PCI) for all-comer CAD show comparable outcomes in terms of cardiac death, TVR, ST, TVMI, and all-cause MI. However, BPS demonstrated higher rates of TVR in follow-ups of more than 5 years.

EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)

Juhani Knuuti et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome The TICO Randomized Clinical Trial

Byeong-Keuk Kim et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

Usman Baber et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

2018 ESC/EACTS Guidelines on myocardial revascularization

Franz-Josef Neumann et al.

EUROPEAN HEART JOURNAL (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting

Francesco Costa et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Combinations of bleeding and ischemic risk and their association with clinical outcomes in acute coronary syndrome

Mohamed O. Mohamed et al.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)

Giuseppe De Luca et al.

EUROINTERVENTION (2019)

Add to Collection

Article Medicine, General & Internal

Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial

Olivier Varenne et al.

LANCET (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients

Fabrizio D'Ascenzo et al.

EUROPEAN HEART JOURNAL (2017)

Add to Collection

Review Cardiac & Cardiovascular Systems

Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds A Review of the Published Data, Practical Recommendations, and Future Directions

Davide Capodanno et al.

JACC-CARDIOVASCULAR INTERVENTIONS (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Thrombogenicity and Early Vascular Healing Response in Metallic Biodegradable Polymer-Based and Fully Bioabsorbable Drug-Eluting Stents

Tobias Koppara et al.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2015)

Add to Collection

Article Medicine, General & Internal

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Marc P. Bonaca et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

Laura Mauri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Cardiac & Cardiovascular Systems

Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium

Roxana Mehran et al.

CIRCULATION (2011)

Add to Collection

Article Medicine, General & Internal

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

Gilles Montalescot et al.

LANCET (2009)

Add to Collection

Article Medicine, General & Internal

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Lars Wallentin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.